Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Management of thalidomide toxicity.

Irene M Ghobrial¹, S Vincent Rajkumar

¹Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.

The Journal of Supportive Oncology

|September 1, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Haematologica·2026

Same author

Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.

Nature chemical biology·2026

Same author

New Insights into the Role of Clonotypic B Cells in Plasma-cell Neoplasia.

Blood cancer discovery·2026

Same author

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Nature medicine·2026

Same author

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights.

American journal of hematology·2026

Same author

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Nature communications·2026

Same journal

Quality of Life and Patterns of Use of Complementary and Alternative Medicines Among Glioma Patients.

The journal of supportive oncology·2015

Same journal

Listening to the voice of patients.

The journal of supportive oncology·2014

Same journal

My mom, the cancer warrior.

The journal of supportive oncology·2014

Same journal

Whole brain radiotherapy for poor prognosis patients with brain metastases: predictably poor results.

The journal of supportive oncology·2014

Same journal

Characterization of skin reactions and pain reported by patients receiving radiation therapy for cancer at different sites.

The journal of supportive oncology·2014

Same journal

Monitoring of health-related quality of life and symptoms in prostate cancer survivors: a randomized trial.

The journal of supportive oncology·2014

See all related articles

Thalidomide shows promise as an anti-cancer drug, particularly for multiple myeloma. Careful management of its side effects, including birth defects and neuropathy, is crucial for safe use in cancer therapy.

Area of Science:

Oncology
Pharmacology

Background:

Thalidomide, once withdrawn due to teratogenicity, is now FDA-approved for erythema nodosum leprosum.
It exhibits immunomodulatory and antiangiogenic properties, suggesting therapeutic potential in oncology.

Purpose of the Study:

To review the incidence and management of thalidomide's side effects.
To discuss precautions and interventions for minimizing thalidomide toxicity in cancer patients.

Main Methods:

Review of clinical trials and literature on thalidomide's use in cancer therapy.
Analysis of reported adverse events and their management strategies.

Main Results:

Thalidomide demonstrates significant activity in multiple myeloma and is under investigation for other malignancies.

Related Experiment Videos

Common toxicities include birth defects, neuropathy, somnolence, rash, fatigue, and constipation.

Dose and duration influence toxicity; doses ≤200 mg/day are generally well-tolerated.

Conclusions:

Thalidomide is a viable antineoplastic agent with ongoing trials in various cancers.
Strict monitoring and dose management are essential to mitigate risks, especially teratogenicity and neuropathy.